4868 RUE LEVY, SUITE 220, SAINT-LAURENT, A8
Investor Presentation
Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Amended material disclosure
Reports Second Quarter 2026 Financial Results and Provides Business Update
2026 Annual Meeting Results - enGene Therapeutics Inc. Shareholder Vote
Annual Report to Security Holders
Q1
Amended Annual Report
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence